Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease.

ABSTRACT:

Background

The thiopurine medications are well established in the treatment of inflammatory bowel disease (IBD). There is significant variation in levels of toxic and therapeutic metabolites. Current data from small or short-term studies support therapeutic drug monitoring (TDM) in assessing azathioprine (AZA) and 6-mercaptopurine (6MP). TDM of thiopurines involves measurement and interpretation of metabolites 6-TGN and 6-MMPR.

Aims

This study aimed to assess long-cterm outcomes of patients on thiopurines following therapeutic drug monitoring.

Methods

A multicenter retrospective observational study of outcomes post thiopurine TDM was conducted. Demographics, disease characteristics, physician global assessment, IBD therapy at baseline TDM and again at 12 months were c

SUBMITTER: Barnes A 

PROVIDER: S-EPMC10011286 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature